Cancer Focused Immutep's Stock Soars On Tuesday - Here's Why
Portfolio Pulse from Vandana Singh
Immutep Limited (NASDAQ:IMMP) reported positive safety and initial efficacy data from the first 90mg dosing of eftilagimod alpha (efti) in combination with paclitaxel in a Phase 2/3 trial for metastatic breast cancer, showing no serious adverse events and a 50% overall response rate. Shares of IMMP soared by 11.90% to $2.63.
March 05, 2024 | 8:57 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Immutep Limited reported positive Phase 2/3 trial results for eftilagimod alpha in metastatic breast cancer, leading to an 11.90% increase in stock price to $2.63.
The positive safety and efficacy data from the trial of eftilagimod alpha in combination with paclitaxel for metastatic breast cancer significantly boosts investor confidence in Immutep's potential, leading to a sharp increase in stock price. The absence of serious adverse events and the reported 50% overall response rate are key factors driving the positive market reaction.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100